Retrospective analysis of gene fusions reveals their potential as prognostic biomarkers in advanced melanoma, indicating their role as therapeutic targets.
A, Fusion event type percentages. B, Linear models assessing the association between TFB and each of the molecular signature scores by cohort, including chromosomal instability score, cytolytic activity (CYT) score, and proliferation score. C, TFB distribution by RECIST groups. CRPR, complete response or partial response; PD, progressive disease; SD, stable disease.
No takes yet. Share an insight, caveat, or question.
Nibeyro et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: